This company listing is no longer active
Protalix BioTherapeutics Toekomstige groei
Future criteriumcontroles 5/6
Belangrijke informatie
129.7%
Groei van de winst
130.6%
Groei van de winst per aandeel
Biotechs winstgroei | 45.5% |
Inkomstengroei | 34.4% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 28 Feb 2023 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2024 | 95 | 38 | N/A | N/A | 1 |
12/31/2023 | 63 | 8 | N/A | N/A | 1 |
12/31/2022 | 48 | -15 | -26 | -25 | N/A |
9/30/2022 | 48 | -18 | -28 | -27 | N/A |
6/30/2022 | 45 | -18 | -21 | -20 | N/A |
3/31/2022 | 43 | -24 | -8 | -6 | N/A |
12/31/2021 | 38 | -28 | -12 | -10 | N/A |
9/30/2021 | 49 | -21 | -14 | -13 | N/A |
6/30/2021 | 48 | -21 | -16 | -14 | N/A |
3/31/2021 | 53 | -14 | -30 | -29 | N/A |
12/31/2020 | 63 | -7 | -27 | -26 | N/A |
9/30/2020 | 61 | -7 | -23 | -22 | N/A |
6/30/2020 | 65 | -6 | -23 | -22 | N/A |
3/31/2020 | 66 | -9 | -20 | -19 | N/A |
12/31/2019 | 55 | -18 | -20 | -19 | N/A |
9/30/2019 | 47 | -24 | -20 | -20 | N/A |
6/30/2019 | 45 | -26 | -3 | -3 | N/A |
3/31/2019 | 38 | -26 | -6 | -6 | N/A |
12/31/2018 | 34 | -26 | -8 | -8 | N/A |
9/30/2018 | 28 | -34 | 13 | 14 | N/A |
6/30/2018 | 23 | -40 | -11 | -10 | N/A |
3/31/2018 | 25 | -32 | -12 | -11 | N/A |
12/31/2017 | 21 | -83 | -11 | -10 | N/A |
9/30/2017 | 19 | -73 | -36 | -35 | N/A |
6/30/2017 | 16 | -69 | -29 | -28 | N/A |
3/31/2017 | 11 | -80 | -32 | -31 | N/A |
12/31/2016 | 9 | -29 | -33 | -32 | N/A |
9/30/2016 | 7 | -35 | N/A | -29 | N/A |
6/30/2016 | 4 | -34 | N/A | -34 | N/A |
3/31/2016 | 3 | -29 | N/A | -27 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: PLX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Winst versus markt: PLX is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: PLX is expected to become profitable in the next 3 years.
Omzet versus markt: PLX's revenue (34.4% per year) is forecast to grow faster than the IL market (4.6% per year).
Hoge groei-inkomsten: PLX's revenue (34.4% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if PLX's Return on Equity is forecast to be high in 3 years time